![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GALNT15 |
Gene summary for GALNT15 |
![]() |
Gene information | Species | Human | Gene symbol | GALNT15 | Gene ID | 117248 |
Gene name | polypeptide N-acetylgalactosaminyltransferase 15 | |
Gene Alias | GALNACT15 | |
Cytomap | 3p25.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | C9JGI4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
117248 | GALNT15 | HCC1 | Human | Liver | HCC | 1.17e-09 | 7.53e-01 | 0.5336 |
117248 | GALNT15 | HCC2 | Human | Liver | HCC | 3.58e-20 | 1.25e+00 | 0.5341 |
117248 | GALNT15 | HCC5 | Human | Liver | HCC | 4.92e-25 | 1.30e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALNT15 | SNV | Missense_Mutation | novel | c.608N>T | p.Ala203Val | p.A203V | Q8N3T1 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALNT15 | SNV | Missense_Mutation | novel | c.1839N>C | p.Lys613Asn | p.K613N | Q8N3T1 | protein_coding | tolerated(0.11) | benign(0.398) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
GALNT15 | SNV | Missense_Mutation | c.625N>T | p.Arg209Trp | p.R209W | Q8N3T1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GALNT15 | SNV | Missense_Mutation | c.195G>T | p.Gln65His | p.Q65H | Q8N3T1 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
GALNT15 | SNV | Missense_Mutation | rs191977190 | c.1315C>T | p.Arg439Cys | p.R439C | Q8N3T1 | protein_coding | deleterious(0.01) | possibly_damaging(0.886) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
GALNT15 | SNV | Missense_Mutation | novel | c.49N>T | p.Leu17Phe | p.L17F | Q8N3T1 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.996) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
GALNT15 | SNV | Missense_Mutation | rs535247367 | c.1183N>A | p.Glu395Lys | p.E395K | Q8N3T1 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
GALNT15 | deletion | Frame_Shift_Del | c.1328_1335delNNNNNNNN | p.Thr443ArgfsTer11 | p.T443Rfs*11 | Q8N3T1 | protein_coding | TCGA-DI-A0WH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
GALNT15 | SNV | Missense_Mutation | c.427G>A | p.Val143Met | p.V143M | Q8N3T1 | protein_coding | tolerated(0.11) | benign(0.054) | TCGA-DD-A73D-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
GALNT15 | SNV | Missense_Mutation | novel | c.1310G>A | p.Arg437Lys | p.R437K | Q8N3T1 | protein_coding | tolerated(1) | benign(0) | TCGA-05-4420-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |